Cellebrite DI announced its half-year 2025 results, reporting revenue of US$220.83 million, a turnaround to net income of US$36.88 million, and the appointment of Thomas E. Hogan as CEO, following his ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” second-quarter ...

Cellebrite (CLBT) boasts strong growth potential with robust financials, digital forensics leadership, and a durable moat.

Cellebrite DI Ltd. (CLBT) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

In recent trading, shares of Cellebrite DI Ltd (Symbol: CLBT) have crossed above the average analyst 12-month target price of $10.00, changing hands for $10.74/share. When a stock reaches the ...

Both FUTU and CLBT are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that FUTU is the superior value option right now. Buy 5 Stocks BEFORE Election Day ...

Cellebrite DI Ltd. (NASDAQ:CLBT) reported revenue of $113.3 million in Q2 2025, up 18% from Q2 2024, driven by subscription revenue growth of 21%.While we acknowledge the risk and potential of ...